勃林格殷格翰（中国）投资有限公司

Chinese investment and holding company of Boehringer Ingelheim, the family-owned German pharmaceutical group headquartered in Ingelheim am Rhein. Oversees the group's Chinese human pharmaceutical, animal health and biopharmaceutical contract manufacturing operations, including its Shanghai biologics site, and markets medicines for cardiometabolic disease, respiratory disease, oncology and central nervous system conditions alongside local research, development and digital health work.